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Background: Multivessel disease (MVD) is common in patients with ST-segment elevation myocardial infarction
(STEMI), but optimal treatment management remains undetermined.
Methods: In this retrospective cohort study, 602 consecutive STEMI patients with MVD were enrolled between
January 1, 2010 and October 1, 2014. Three hundred and eighty-two patients underwent culprit-only revascularization
and 220 underwent staged complete revascularization. Primary end points were a composite of cardiac mortality or
nonfatal reinfarction.
Results: The mean duration of follow-up was 35 months (12–71 months). Following multivariate analysis, staged
complete revascularization was associated with a lower rate of the composite of cardiac mortality or nonfatal
reinfarction [HR: 0.430, 95 % CI: 0.197–0.940, P = 0.034] and unplanned repeat revascularization [HR: 0.343, 95 %
CI: 0.166–0.708, P = 0.004] compared with culprit-only revascularization.
Conclusions: Compared with culprit-only revascularization, staged complete revascularization significantly
reduced the rate of the composite of cardiac mortality or nonfatal reinfarction, and the need for unplanned
repeat revascularization.
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Primary percutaneous coronary intervention (P-PCI) of the
culprit artery is widely used in patients with ST-segment
elevation myocardial infarction (STEMI). Approximately
50 % of STEMI patients have multivessel disease (MVD)
[1, 2]. Non-culprit lesions are not just “bystanders”, as a
pathophysiological inflammation process in acute myocar-
dial infarction could cause plaque instability [3, 4]. Previous
research has also shown that STEMI patients with MVD
have higher mortality rates and a greater incidence of non-
fatal reinfarction than those without MVD [1, 2]. However,
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(http://creativecommons.org/publicdomain/zeremains undetermined [5–7]. Although a number of ran-
domized controlled trials (RCTs) [8–11], including the
PRAMI [9], CVLPRIT [10] and DANAMI-3—PRIMULTI
[11] trials, have indicated the clear benefits of complete
PCI, other RCTs [12–14], including the PRAGUE-13 trial
[12], found no difference between complete and culprit-
only revascularization in STEMI patients with MVD. Fur-
thermore, observational studies [15–21] and meta-analyses
[22–24] also demonstrated conflicting results.
The present study aimed to determine the benefits and
safety of staged complete revascularization in STEMI
patients with MVD undergoing P-PCI.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Study design and setting
This was a retrospective cohort study, and included con-
secutive STEMI patients who were hospitalized and
underwent PCI at Shengjing Hospital of China Medical
University (Shenyang, China) between January 1, 2010
and October 31, 2014. Six hundred and two consecutive
cases were selected in this large-scale hospital in
Northeast China. Firstly, the investigators identified all
consecutive PCI patients from PACS (Picture Archiving
and Communication Systems) of the interventional im-
aging data and assigned each case a unique study ID.
The investigators then abstracted comprehensive clinical
data and procedural data using electronic medical re-
cords. Abstracted elements included patient demo-
graphic characteristics, past cardiac and noncardiac
history, patient clinical characteristics on hospital admis-
sion, laboratory measurements, procedure-related com-
plications and use of cardiac medications during the
index hospitalization and at discharge. Killip classifica-
tion was introduced [5]. All venous blood samples were
obtained on admission and tested using autoanalyzers in
the core laboratory of Shengjing Hospital and standard
techniques. Left ventricular ejection fraction (LVEF) was
determined by echocardiography during hospitalization.
Procedural data from surgical records in PCI cases were
completed by operators. Angiographic variables were es-
timated visually or by a quantitative computer analysis
system. Thrombolysis In Myocardial Infarction (TIMI)
flow grade was determined as defined previously [25].
Clinical follow-up was assessed in October 2015 by hos-
pital visits or phone interviews with the patient’s general
practitioner/cardiologist, the patient or his/her family.
All events were obtained from the patients’ medical
records. If these data were unavailable, statuses were
ascertained by a telephone call to the patient’s referring
hospital physician. All events were adjudicated and clas-
sified by two cardiologists.
Participants and procedures
We identified 1056 STEMI patients treated with P-PCI.
Patients who were eligible for P-PCI met the following
criteria: (1) chest pain present less than 12 h from onset
of pain to time of catheterization, (2) significant ST-
segment elevation (at least 0.1 mV in two or more stand-
ard leads or at least 0.2 mV in two or more contiguous
precordial leads) or a new left bundle branch block. After
confirmation of STEMI, P-PCI was immediately under-
taken according to current guideline recommendations
and operators’ routine practice. Operators decided on the
use of aspiration thrombectomy, heparin, or glycoprotein
IIb/IIIa inhibitor. The culprit artery was determined using
ECG, echocardiography and angiographic findings by each
operator. For inclusion in the present study, patients hadto have MVD, which was defined as the presence of angio-
graphic diameter stenosis of 50 % or greater in at least one
non-culprit major epicardial coronary artery or its major
branches (with diameter ≥2 mm). Exclusion criteria in-
cluded (1) single vessel disease, (2) cardiogenic shock, (3)
any type of stent thrombosis, (4) previous coronary artery
bypass grafting (CABG), (5) unsuitable for treatment with
P-PCI, (6) chronic total occlusion as the only significant
non-culprit lesion, (7) non-culprit lesion in coronary ar-
tery branches 2 mm or smaller in diameter. The study
population was subdivided into (1) the culprit-only revas-
cularization group (CR group), in which only the culprit
lesion received PCI during the index catheterization or
hospitalization; (2) the staged complete revascularization
group (SR group), in which, after culprit lesion PCI, a
planned additional non-culprit lesion PCI was per-
formed during the index hospitalization, or within 1
month after discharge, regardless of symptoms or
evidence of ischemia. Periprocedural and postproce-
dural anti-platelet treatments and other cardiovascular
medications were administered in accordance with
current guidelines [5, 7].
Clinical end points
The primary end point was a composite of cardiac mor-
tality or nonfatal reinfarction. Secondary end points
were all-cause mortality, cardiac mortality, nonfatal rein-
farction and unplanned repeat revascularization, includ-
ing any unplanned repeat PCI or surgical bypass of
target or non-target vessels. The safety end points were
periprocedure-related complications, including BARC 3
or 5 bleeding, contrast-induced nephropathy, stroke, and
acute or subacute stent thrombosis during the index
hospitalization. Stroke was defined as an acute event of
non-hemorrhagic cerebrovascular origin causing focal or
global neurologic dysfunction lasting >24 h, which was
confirmed by both clinical and radiographic criteria.
Contrast-induced nephropathy was defined as an increase
in serum creatinine concentration ≥0.5 mg/dl (44.2
mmol/l) or ≥25 % above baseline 72 h after exposure to
the contrast medium. All other end points were defined
by standardized definitions [26, 27]. This study complies
with the Declaration of Helsinki, and Shengjing Hospital
of China Medical University Research Ethics Committee
approved the research protocol. Written informed consent
was formally obtained from all participants.
Statistical analysis
Quantitative variables with normal distribution were
represented as mean ± standard deviation (SD) and com-
pared with the independent samples t-test. Quantitative
variables without normal distribution were represented
as median [interquartile range, IQR] and compared with
the Mann-Whitney U-test. Normal distribution was
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Categorical variables were represented as counts and
proportions (%) and compared using the chi-square test.
Event-free survival was estimated in the two groups
from Kaplan–Meier curves and compared using the
Log-Rank Test. Cox proportional-hazards regression
modeling was used to analyze the effects of variables on
event-free survival. Variables in Table 1 with P ≤ 0.1 at
the univariate analysis were “entered” into the model
(Table 3). These variables included age, gender, current
smoker, and previous MI. Results were reported as haz-
ard ratios (HRs) with associated 95 % confidence inter-
vals (CIs). All tests were two-sided, and the statistical
significance was defined as P < 0.05. All statistical ana-




Between January 1, 2010 and October 1, 2014, a total of
1,056 patients were treated with P-PCI for STEMI in
our center. Figure 1 represents the flowchart for patient
selection. The final study cohort consisted of 602 pa-
tients, of whom 382 (63.5 %) received culprit-only revas-
cularization and 220 (36.5 %) received staged complete
revascularization. For the SR group, the timing of non-
culprit lesion PCI was during the index hospitalizationTable 1 Demographics and baseline clinical characteristics,
means ± SD, or N (%)
CR, n = 382 SR, n = 220 P
Age, yrs 64.6 ± 12.0 62.7 ± 11.5 0.052
Male 257 (67.3) 164(74.5) 0.061
Medical history
Diabetes 101 (26.4) 70 (31.8) 0.159
Hypertension 194 (50.8) 120 (54.5) 0.374
Hypercholesterolemia 100 (26.2) 56 (25.5) 0.845
Current smoker 194 (50.8) 128 (58.2) 0.080
Previous PCI 14 (3.7) 10 (4.5) 0.595
Previous MI 13 (3.4) 14 (6.4) 0.091
Killip class II/III on admission 27 (7.1) 13 (5.9) 0.582
Systolic blood pressure on
admission, mmHg
128.2 ± 22.0 129.9 ± 24.0 0.392
Heart rate on admission, bpm 77.3 ± 16.8 77.8 ± 14.5 0.703
LVEF, % 54.0 ± 9.1 53.6 ± 9.1 0.662
Symptom to balloon time, h 6 (4,9) 6 (3,9) 0.851
Anterior MI 165 (43.2) 103 (46.8) 0.389
Three-vessel disease 160 (41.9) 106 (48.2) 0.134
Intra-aortic Balloon Pump 31 (8.1) 17 (7.7) 0.866
MI myocardial infarction, bpm beats per minute, h hourusing a staged procedure (n = 208) and after index
hospitalization but within 1 month (n = 12).
Basic characteristics
Clinical characteristics in the two groups were generally
similar and are shown in Table 1. Periprocedural details
and discharge medication are shown in Table 2. Patients
in the SR group had more stents and longer total stent
length. Discharge medication was similar between the
two groups (Table 2).
Clinical Outcome
All patients were followed for a mean duration of 35
months (12–71 months). The length of follow-up in the
CR group was 34 months (12–69 months), and was 36
months (12–71 months) in the SR group. During the
follow-up period, 31 events of cardiac mortality/nonfatal
myocardial reinfarction events, 17 events of cardiac mor-
tality, 14 events of nonfatal myocardial reinfarction, 19
events of all-cause mortality, and 42 events of unplanned
repeat revascularization were observed in the CR group;
8 events of cardiac mortality/nonfatal myocardial rein-
farction, 4 events of cardiac mortality, 4 events of nonfa-
tal myocardial reinfarction, 5 events of all-cause
mortality, and 9 events of unplanned repeat revasculari-
zation were observed in the SR group. The composite of
cardiac mortality or nonfatal reinfarction was signifi-
cantly lower in the SR group compared with the CR
group [HR: 0.427, 95 % CI: 0.196–0.929, P = 0.032], and
unplanned repeat revascularization showed a similar
trend [HR: 0.349, 95 % CI: 0.170–0.717, P = 0.004] (Fig. 2;
Table 3). After adjusting for covariates (Model 1), the SR
group was still associated with a lower rate of the com-
posite of cardiac mortality or nonfatal reinfarction [HR:
0.430, 95 % CI: 0.197–0.940, P = 0.034] and unplanned
repeat revascularization [HR: 0.343, 95 % CI: 0.166–
0.708, P = 0.004] compared with the CR group (Table 3).
There were no statistically significant differences in the
other endpoints between the two groups (Table 3).
Periprocedure-related complications were not signifi-
cantly different (Table 4).
Discussion
The present study determined the effects of different
treatment strategies on STEMI patients with MVD
in a real-world clinical setting. The main findings
were as follows: (1) staged complete revasculariza-
tion significantly reduced not only the rate of the
composite of cardiac mortality or nonfatal reinfarc-
tion, but also the need for unplanned repeat revascu-
larization; (2) no significant differences in all-cause
mortality, cardiac mortality or nonfatal reinfarction
were observed between the treatment strategies; (3)
Fig. 1 Flow diagram of participant selection. 330 with single vessel disease, 70 with other exclusion criteria, and 44 without follow-up were excluded.
The final study cohort consisted of 602 patients, of whom 382 received culprit-only revascularization and 220 received staged complete
revascularization. STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
grafting; N-IRA, non-Infarct-Related Artery
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increase periprocedure-related complications.
Toyota et al. analyzed 1311 STEMI patients with
MVD undergoing P-PCI from the CREDO-Kyoto AMI
Registry in Japan (681 in the staged PCI group versus
630 in the culprit-only PCI group), and reported that
staged PCI was associated with a lower 5-year composite
of cardiac mortality and myocardial infarction compared
with culprit-only PCI [HR: 0.67, 95 % CI: 0.44–0.99, P =
0.045] [19]. Our findings also showed a lower composite
of cardiac mortality and nonfatal reinfarction in the SR
group. A similar conclusion was found in the CvLPRIT
and DANAMI-3—PRIMULTI trials [10, 11]. However,
no studies have found significant differences in cardiac
mortality [8–12, 19] between the treatment groups. Fur-
thermore, most studies [8–12, 17, 19, 20] found no signifi-
cant differences in nonfatal reinfarction, except for the
PRAMI trial [9] and a recent meta-analysis [23]. Our
study also failed to find significant differences in cardiacmortality and nonfatal reinfarction between the two
groups. It was demonstrated that staged complete revas-
cularization significantly reduced the need for unplanned
repeat revascularization; however, the Japanese study [19]
and CvLPRIT trial [10] found no significant differ-
ences, and the proportion of patients with three-vessel
disease may have played an important role. There was
a higher proportion of three-vessel disease in the CR
group in our study than in the other two previous
studies. In other words, the higher the proportion of
three-vessel disease, the higher the proportion of
ischemia-driven unplanned repeat revascularizations.
Meta-analyses have also confirmed that multivessel
PCI will reduce the need for repeat revascularization
[22–24]. Different to other studies [17–19], our study
found no significant differences in all-cause mortality.
It is possible that the follow-up duration in our study
was too short to detect significant differences in all-
cause mortality: 3-year follow-up in our study,
Table 2 Periprocedural details and discharge medication,
median (IQR), or N (%)
CR, n = 382 SR, n = 220 P
Percutaneous coronary intervention
TIMI flow grade 0/1 on arrival 288 (75.4) 165 (75.0) 0.914
TIMI flow grade 3 post-PCI 375 (98.2) 218 (99.1) 0.369
Number of stents 1 (1,2) 3 (2,4) <0.001
Stent type 0.211
No stenting 9 (2.4) 1 (0.5)
Bare metal 2 (0.5) 1 (0.5)
Drug-eluting 371 (97.1) 218 (99.1)
Total stent length for all lesions
treated, mm
36 (24,57) 79 (54,109) <0.001
Lesion site in culprit vessel 0.700
Left anterior descending artery 169 (44.2) 95 (43.2)
Left circumflex artery 48 (12.6) 33 (15.0)
Right coronary artery 165 (43.2) 92 (41.8)
Thrombus aspiration catheter used 55 (14.4) 27 (12.3) 0.464
Use of glycoprotein IIb/IIIa inhibitor 142 (37.2) 127 (42.3) 0.217
Medical treatment at discharge
Aspirin 376 (98.4) 217 (98.6) 0.840
Clopidogrel 373 (97.6) 213 (96.8) 0.544
Ticagrelor 5 (1.3) 5 (2.3) 0.373
Statin 358 (93.7) 203 (92.3) 0.498




224 (58.6) 133 (60.5) 0.662
Calcium-channel blocker 24 (6.3) 9 (4.1) 0.255
Nitrate 39 (10.2) 16 (7.3) 0.228
Nicorandil 20 (5.2) 6 (2.7) 0.145
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other two studies [18, 19]. In addition, the sample size
in our study was relatively small, 602 individuals com-
pared with 8822 and 1311 in the other two studies [18,
19]. Accordingly, adequately powered randomized
studies should be performed to obtain meaningful con-
clusions, such as in the COMPLETE trial (Clinical-
Trials.gov NCT01740479).
The safety concerns regarding complete revasculariza-
tion include the risk of procedural complications, longer
procedural time, contrast nephropathy, and stent throm-
bosis which may increase in a prothrombotic and pro-
inflammatory state in the presence of STEMI. Despite
this, our study showed no increase in major bleeding,
contrast-induced nephropathy, stroke, acute or sub-
acute stent thrombosis. This was consistent with previous
studies [8, 10–12, 19].There are still several problems related to the treat-
ment of STEMI. First, is staged complete revasculari-
zation better than "one-time" complete revascularization?
While analysis from the HORIZONS-AMI trial preferred
staged complete revascularization [15], other studies
found "one-time" complete revascularization safe and
effective [20, 21]. Second, what is the appropriate
timing of staged revascularization? Different studies
had different time cut-off points; however, no study
could confirm a favored time cut-off point. Third,
should fractional flow reserve (FFR) or a non-invasive
physiological stress test be used to determine indica-
tions for staged revascularization in addition to angi-
ography? FFR measurements of non-culprit lesions
could be performed immediately [28] or several days
or weeks [7] after treatment of the culprit vessel. To
date, studies with FFR as the reference [11, 13, 14] did
not have clearer conclusions than those without FFR as the
reference [8–10]. The COMPARE ACUTE trial (Clinical-
Trials.gov NCT01399736), an ongoing prospective ran-
domized study comparing a FFR-guided multivessel PCI
undertaken during primary PCI of the culprit vessel only,
may help us to define the role of FFR in STEMI patients
with MVD. Fourth, do the benefits extend to non-
culprit stenoses of less than 70 % or 50 %? The level of
non-culprit stenosis at which the risks of PCI surpass
the benefits is still uncertain. In addition to FFR, intra-
coronary imaging such as an intravascular ultrasound
study (IVUS) and optical coherence tomography (OCT)
could be useful tools for non-culprit lesion revasculari-
zation. IVUS and OCT could help us describe in vivo
the pathological morphology of plaque associated with
an impaired myocardial blush and slow flow leading to
a worse prognosis [29]. As for the use of IVUS and
OCT, a per-patient tailored therapy may be achieved.
Limitations
This study had several limitations. First, the study was
retrospective and observational, thus potential confounders
and selection bias could not be completely adjusted. Sec-
ond, this was a single center study. Third, the significance
of non-culprit lesions was assessed only on angiography,
and ischemia tests such as FFR were absent. Fourth, the
long symptom to balloon time in this study may have had
an impact on the study results, as analysis of the
HORIZONS-AMI trial results suggested that a delay in
mechanical reperfusion therapy during STEMI is associ-
ated with greater injury to the microcirculation [30], and
another study showed that a symptom-onset-to-balloon
time >4 h was an independent predictor of one-year mor-
tality [31]. Finally, the incidence of the primary composite
end-point was quite low during the follow-up period. The
low number of events may be a limitation in the overall
interpretation of the study results.
Fig. 2 Kaplan-Meier survival curves free from (a) cardiac mortality/nonfatal reinfarction, (b) cardiac mortality, (c) nonfatal reinfarction, (d) all-cause
mortality, (e) unplanned repeat revascularization according to the different groups. SR, staged complete revascularization group; CR, culprit-only
revascularization group
Table 3 Univariate and multivariate analysis of the effects of different treatment strategies at follow-Up, N (%)
No. patients with event Univariate analysis Multivariate analysis*
CR SR HR (95 % CI) P HR (95 % CI) P
Primary end points
Cardiac mortality/Nonfatal reinfarction 31 (8.1) 8 (3.6) 0.427 (0.196–0.929) 0.032 0.430 (0.197–0.940) 0.034
Secondary end points
Cardiac mortality 17 (4.5) 4 (1.8) 0.400 (0.135–1.190) 0.100 0.440 (0.147–1.319) 0.143
Nonfatal reinfarction 14 (3.7) 4 (1.8) 0.467 (0.153–1.418) 0.179 0.442 (0.143–1.365) 0.156
All-cause mortality 19 (5.0) 5 (2.3) 0.442 (0.165–1.185) 0.105 0.489 (0.181–1.321) 0.158
Unplanned repeat revascularization 42 (11.0) 9 (4.1) 0.349 (0.170–0.717) 0.004 0.343 (0.166–0.708) 0.004
*Adjusted for age, diabetes, hypertension, Killip class II/III on admission, systolic blood pressure on admission, heart rate on admission, symptom to balloon time,
and anterior MI
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Table 4 Periprocedure-related complications, N (%)
CR (n = 382) SR (n = 220) P
BARC 3 or 5 bleeding 2 (0.5) 4 (1.8) 0.124
Contrast-induced nephropathy 13 (3.4) 5 (2.3) 0.433
Stroke 3 (0.8) 0 0.188
Acute or subacute stent thrombosis 1 (0.3) 0 0.448
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In STEMI patients with MVD, staged complete revasculari-
zation for angiographically significant non-culprit lesions
was associated with a significantly lower composite of
cardiac mortality or nonfatal reinfarction and unplanned
repeat revascularization.
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